Monoclonal antibodies: technologies for early discovery and engineering

Area of Science:

• Life Sciences
• Biotechnology
• Immunology

Background:

• Antibodies possess unique architecture and diversity, enabling high specificity and affinity for biochemical targets.
• Monoclonal antibody (mAb) technology, combined with recombinant DNA and protein expression, links antibody genotype to phenotype.
• The power of mAbs is amplified by selecting high-affinity binders from combinatorial libraries, leading to numerous clinical applications.

Purpose of the Study:

• To review antibody biology, focusing on structure-function relationships, diversity, and affinity maturation.
• To discuss requirements for therapeutic antibody discovery and engineering, emphasizing in vitro display technologies.
• To highlight the interplay between antibody biology, technological advancements, and computational strategies in antibody development.

Main Methods:

• Exploration of various in vitro display technologies (phage, mammalian cell, cell-free) for antibody identification based on affinity and function.
• Discussion of antibody engineering techniques to enhance affinity, half-life, and manufacturability.
• Integration of high-throughput, big data, and in silico approaches in antibody discovery and development.

Main Results:

• Antibody biology provides inspiration for the development of novel technological approaches.
• In vitro display technologies facilitate the identification and optimization of lead antibody candidates.
• Engineering strategies can improve antibody characteristics for therapeutic and diagnostic use.

Conclusions:

• Antibodies are central to targeted therapeutics, diagnostics, and life science research.
• The synergy between antibody biology and advanced technologies drives innovation in antibody discovery and engineering.
• Computational and high-throughput methods are increasingly crucial for harnessing the full potential of antibodies.